Sen. Bernie Sanders (I-Vt.) on Monday demanded that President Donald Trump keep his campaign promise to force pharmaceutical companies to lower the costs of medications. (Photo: TaxRebate.org.uk/Flickr/cc)
Jul 09, 2018
Sen. Bernie Sanders (I-Vt.) on Monday called on President Donald Trump to "stop just talking about high drug prices" and actually "do something" after the president whined on Twitter about Big Pharma raising prescription drug prices while continuing to flout his campaign promise lower costs for consumers.
Sanders tweeted:
\u201cIf you are serious about this issue, tell your Republican pals in Congress to pass bills requiring Medicare to negotiate drug prices and enabling the importation of safe, low-cost drugs from Canada and other countries. (2/2)\u201d— Bernie Sanders (@Bernie Sanders) 1531162645
The senator was responding to an afternoon tweet in which Trump referenced reports from last week that Pfizer had raised the price of several drugs for the second time this year:
\u201cPfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!\u201d— Donald J. Trump (@Donald J. Trump) 1531156109
Although Trump had vowed to take on the pharmaceutical industry during his race to the Oval Office, as Bloomberg noted Monday, "so far his most-noticed efforts have been using Twitter and stump speeches to call out pharmaceutical companies, rather than enacting major new policies."
In mid-May, the president unveiled a drug plan that critics immediately denounced as "pharma-friendly." As Common Dreams reported, "rather than allowing the government to negotiate lower drug prices--a proposal backed by 92 percent of Americans--Trump's plan vaguely promises to 'encourage innovation' in the private sector while pursuing 'reforms' to Medicare to promote 'greater flexibility.'"
As Bloomberg put it, "Five weeks ago, Trump said that drugmakers would announce 'voluntary, massive' cuts in drug prices in two weeks. So far, no such announcement from the industry has happened."
In fact, as Politicopointed out last week:
A Wells Fargo report found 104 price increases in June and the first two days of July, with an average jump of 31.5 percent and a median increase of 9.4 percent. That followed 48 increases in May. The list price hikes don't factor in discounts that companies may provide to some insurance companies and patients.
The across-the-board increases cast doubt on whether Trump and Health and Human Services Secretary Alex Azar can pressure manufacturers to voluntarily drop prices without the threat of specific consequences.
Azar responded to Trump's tweet on Monday with adeclaration that "change is coming to drug pricing, whether painful or not for pharmaceutical companies," while offering no new plans to force such changes.
Meanwhile, Sanders--who has slammed Trump's drug plan as "lukewarm"--and several top congressional Democrats in October introduced actual legislation, officially titled the Medicare Drug Price Negotiation Act of 2017 (pdf), that would enable the Department of Health and Human Services to negotiate lower prescription drug prices under Medicare Part D.
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. Join with us today! |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sen. Bernie Sanders (I-Vt.) on Monday called on President Donald Trump to "stop just talking about high drug prices" and actually "do something" after the president whined on Twitter about Big Pharma raising prescription drug prices while continuing to flout his campaign promise lower costs for consumers.
Sanders tweeted:
\u201cIf you are serious about this issue, tell your Republican pals in Congress to pass bills requiring Medicare to negotiate drug prices and enabling the importation of safe, low-cost drugs from Canada and other countries. (2/2)\u201d— Bernie Sanders (@Bernie Sanders) 1531162645
The senator was responding to an afternoon tweet in which Trump referenced reports from last week that Pfizer had raised the price of several drugs for the second time this year:
\u201cPfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!\u201d— Donald J. Trump (@Donald J. Trump) 1531156109
Although Trump had vowed to take on the pharmaceutical industry during his race to the Oval Office, as Bloomberg noted Monday, "so far his most-noticed efforts have been using Twitter and stump speeches to call out pharmaceutical companies, rather than enacting major new policies."
In mid-May, the president unveiled a drug plan that critics immediately denounced as "pharma-friendly." As Common Dreams reported, "rather than allowing the government to negotiate lower drug prices--a proposal backed by 92 percent of Americans--Trump's plan vaguely promises to 'encourage innovation' in the private sector while pursuing 'reforms' to Medicare to promote 'greater flexibility.'"
As Bloomberg put it, "Five weeks ago, Trump said that drugmakers would announce 'voluntary, massive' cuts in drug prices in two weeks. So far, no such announcement from the industry has happened."
In fact, as Politicopointed out last week:
A Wells Fargo report found 104 price increases in June and the first two days of July, with an average jump of 31.5 percent and a median increase of 9.4 percent. That followed 48 increases in May. The list price hikes don't factor in discounts that companies may provide to some insurance companies and patients.
The across-the-board increases cast doubt on whether Trump and Health and Human Services Secretary Alex Azar can pressure manufacturers to voluntarily drop prices without the threat of specific consequences.
Azar responded to Trump's tweet on Monday with adeclaration that "change is coming to drug pricing, whether painful or not for pharmaceutical companies," while offering no new plans to force such changes.
Meanwhile, Sanders--who has slammed Trump's drug plan as "lukewarm"--and several top congressional Democrats in October introduced actual legislation, officially titled the Medicare Drug Price Negotiation Act of 2017 (pdf), that would enable the Department of Health and Human Services to negotiate lower prescription drug prices under Medicare Part D.
Sen. Bernie Sanders (I-Vt.) on Monday called on President Donald Trump to "stop just talking about high drug prices" and actually "do something" after the president whined on Twitter about Big Pharma raising prescription drug prices while continuing to flout his campaign promise lower costs for consumers.
Sanders tweeted:
\u201cIf you are serious about this issue, tell your Republican pals in Congress to pass bills requiring Medicare to negotiate drug prices and enabling the importation of safe, low-cost drugs from Canada and other countries. (2/2)\u201d— Bernie Sanders (@Bernie Sanders) 1531162645
The senator was responding to an afternoon tweet in which Trump referenced reports from last week that Pfizer had raised the price of several drugs for the second time this year:
\u201cPfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!\u201d— Donald J. Trump (@Donald J. Trump) 1531156109
Although Trump had vowed to take on the pharmaceutical industry during his race to the Oval Office, as Bloomberg noted Monday, "so far his most-noticed efforts have been using Twitter and stump speeches to call out pharmaceutical companies, rather than enacting major new policies."
In mid-May, the president unveiled a drug plan that critics immediately denounced as "pharma-friendly." As Common Dreams reported, "rather than allowing the government to negotiate lower drug prices--a proposal backed by 92 percent of Americans--Trump's plan vaguely promises to 'encourage innovation' in the private sector while pursuing 'reforms' to Medicare to promote 'greater flexibility.'"
As Bloomberg put it, "Five weeks ago, Trump said that drugmakers would announce 'voluntary, massive' cuts in drug prices in two weeks. So far, no such announcement from the industry has happened."
In fact, as Politicopointed out last week:
A Wells Fargo report found 104 price increases in June and the first two days of July, with an average jump of 31.5 percent and a median increase of 9.4 percent. That followed 48 increases in May. The list price hikes don't factor in discounts that companies may provide to some insurance companies and patients.
The across-the-board increases cast doubt on whether Trump and Health and Human Services Secretary Alex Azar can pressure manufacturers to voluntarily drop prices without the threat of specific consequences.
Azar responded to Trump's tweet on Monday with adeclaration that "change is coming to drug pricing, whether painful or not for pharmaceutical companies," while offering no new plans to force such changes.
Meanwhile, Sanders--who has slammed Trump's drug plan as "lukewarm"--and several top congressional Democrats in October introduced actual legislation, officially titled the Medicare Drug Price Negotiation Act of 2017 (pdf), that would enable the Department of Health and Human Services to negotiate lower prescription drug prices under Medicare Part D.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.